spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Rebif 

 HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Aug 2017
European Commission Grants Approval for Mavenclad (Cladribine Tablets)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Jun 2012
EMD Serono, Inc. Strengthens Leadership Teams with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2012
Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA(TM) (alemtuzumab) for Multiple Sclerosis
Biopharmaceuticals Neurology FDA Regulatory
 HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada(TM)*) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 May 2011
EMD Serono President and CEO Fereydoun Firouz Resigns
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2010
FDA Approves EGRIFTA(TM) (Tesamorelin for Injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients With Lipodystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jan 2010
Two-Year Results From CLARITY Study with Cladribine Tablets in Multiple Sclerosis Published in The New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 May 2009
Merck Serono Initiates SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 May 2009
Merck Serono Launches Glucophage Powder in First European Countries
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 21 Apr 2009
Merck Serono Launches Kuvan(R) in Europe
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2009
Merck Serono Launches Strategic Venture Capital Fund
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Feb 2009
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jan 2009
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Jan 2009
Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Dec 2008
Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Oct 2008
EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Sep 2008
Merck Serono's Kuvan(R) Recommended for European Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Sep 2008
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Sep 2008
Betaseron(R) to Offer the Thinnest Needle in Multiple Sclerosis
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Biopharmaceuticals Distribution
 HSMN NewsFeed - 10 Jun 2008
Merck Serono's Rebif(R) Celebrates 10th Anniversary
BIopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals
 HSMN NewsFeed - 5 May 2008
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva(R) in the Treatment of Psoriasis Published in the British Journal of Dermatology
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX(R) (interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Mar 2008
Merck Serono Launches Cyanokit(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2007
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Oct 2007
Study Showed Patients Using COPAXONE(R) Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif(R) in Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 3 May 2007
Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Apr 2007
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Apr 2007
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 24 Jan 2007
Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jan 2007
Merck KGaA Acquires Majority Shareholding in Serono S.A.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Dec 2006
Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Dec 2006
Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Oct 2006
Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Sep 2006
Merck KgaA to Acquire Serono
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Sep 2006
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 21 Aug 2006
First Patient Enrolled in Study to Evaluate Impact of Regular Neutralizing Antibody (NAb) Testing on Multiple Sclerosis Treatment Patterns
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Aug 2006
Serono Announces Results From Pivotal Phase III Clinical Trial of Its Proprietary Recombinant Human Growth Hormone in the Treatment of HARS at the XVI International AIDS Conference
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 10 Jul 2006
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 9 May 2006
Serono Announces New Appointments to its Executive Management Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2006
Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 15 Mar 2006
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 24 Jan 2006
Serono's Gonal-f(R) Approved in Japan for the Treatment of Male Hypogonadotropic Hypogonadism
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Jan 2006
Serono Completes Second Phase III Trial of its Proprietary Recombinant Human Growth Hormone for HIV-Associated Adipose Redistribution Syndrome (HARS)
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 74

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 74 additional stories matching:
Rebif
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.